AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Spironolactone: Effective Therapy for Acne and More

Description

The presentation discusses the use of spironolactone, a medication primarily known for treating hypertension, for dermatological conditions, particularly acne, hirsutism, and hidradenitis suppurativa (HS). Despite being introduced in 1960, research on its efficacy in treating these conditions has surged in recent years. Various studies indicate that spironolactone may be beneficial as an anti-androgen treatment for acne, with dosing typically ranging from 50 to 200 mg. Clinical guidelines have evolved, providing a conditional recommendation for acne treatment based on a balanced assessment of potential benefits and risks. Evidence suggests that spironolactone can enhance outcomes in acne when used alone or in combination with other therapies. The drug also shows promise for addressing hirsutism, though it may require higher doses and potential combination with other anti-androgens for optimal effectiveness. For HS, treatment with spironolactone has demonstrated positive outcomes, particularly in patients with moderate disease. Overall, spironolactone is being increasingly recommended for these conditions, but ongoing research and consideration of potential side effects, notably menstrual irregularity, remain critical in clinical decision-making.

View more

Conclusions

  • Spironolactone is increasingly supported as an effective treatment for acne, particularly in women with androgen-sensitive conditions.
  • Current guidelines from the AAD recommend spironolactone for acne with a conditional recommendation due to benefits being closely balanced with risks.
  • Efficacy of spironolactone for acne is noted, but evidence is based on limited quality studies and may require combination with other therapies for better results.
  • In studies, spironolactone doses between 50-200 mg per day show varied patient responses, with higher doses linked to more side effects, particularly menstrual irregularities.
  • Spironolactone demonstrates some effectiveness in treating hirsutism, often requiring higher doses and potentially enhanced when used with other anti-androgens.
  • The drug shows promise for hidradenitis suppurativa as well, helping many patients achieve significant improvements over time.
  • Predictions of successful response to spironolactone can be influenced by patient history, including previous treatments and the baseline severity of their conditions.
  • Zaenglein AL et al. J Am Acad Dermatol 2016; 74: 945.
  • Reynolds RV et al. J Am Acad Dermatol 2024; in press.
  • Brown J et al. Cochrane Database Syst Rev 2009: CD000194.
  • Layton AM et al. Am J Clin Dermatol 2017; 18: 169.
  • Garg V et al. J Am Acad Dermatol 2021; 84: 1348.
  • Santer M et al. BMJ 2023; 2381: 3074349.
  • Isvy-Joubert A et al. Eur J Dermatol 2017; 27: 393.
  • Barbieri JS et al. J Am Acad Dermatol 2019; 81: 848.
  • Moghetti P et al. J Clin Endocrinol Metab 2000; 85: 89.
  • Kelestimur F et al. Eur J Endocrinol 2004; 150: 351.
  • Lee A, Fischer G. Australas J Dermatol 2015; 56: 192.
  • Golbari NM et al. J Am Acad Dermatol 2019; 80: 114.
  • Quinlan C et al. Clin Exp Dermatol 2020; 45: 464.